| 证券代码: | 300151 | 证券简称：昌红科技 | | 公告编号：2023-069 | | --- | --- | --- | --- | --- | | 债券代码: | 123109 | 债券简称: | 昌红转债 | | 深圳市昌红科技股份有限公司 派送现金股利：P1=P0-D； 1 关于可转换公司债券转股价格调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会《关于同意深圳市昌红科技股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2021〕609 号）核准，深 圳市昌红科技股份有限公司（以下简称"公司"）于 2021 年 4 月 1 日向不特定对 象发行可转债 460.00 万张。根据《深圳市昌红科技股份有限公司创业板向不特 定对象发行可转换公司债券募集说明书》（以下简称《募集说明书》）， 在本次发 行之后，当公司发生派送股票股利、转增股本、增发新股或配股（不包括因本次 发行的可转换公司债券转股而增加的股本）使公司股份发生变化及派送现金股 ...

| 证券代码: | 300151 | 证券简称：昌红科技 | 公告编号：2023-071 | | --- | --- | --- | --- | | 债券代码: | 123109 | 债券简称:昌红转债 | | 深圳市昌红科技股份有限公司 关于控股股东、实际控制人及其一致行动人持股比例 被动稀释超过 1%的提示性公告 1、本次权益变动为公司向特定对象发行股份导致的控股股东、实际控制人 及其一致行动人持股比例被动稀释，不触及要约收购，不涉及股东股份增持或者 减持。 2、本次权益变动不会导致公司控股股东、实际控制人发生变化，不会影响 公司的治理结构和持续经营。 经中国证券监督管理委员会出具的《关于同意深圳市昌红科技股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2023〕1379 号），深圳市昌红科 技股份有限公司（以下简称"公司"）本次向特定对象发行 A 股股票 30,000,000 股。根据中国证券登记结算有限责任公司深圳分公司于 2023 年 9 月 4 日出具的 《股份登记申请受理确认书》，本次发行完成后，公司总股本（人民币普通股） 由 502,508,027 股增加至 532,508,027 股 ...

| 姓名 | 职务 | 本次发行前 | | 本次发行后 | | | --- | --- | --- | --- | --- | --- | | | | 股份数量（股） | 所占比例 | 股份数量（股） | 所占比例 | | 李焕昌 | 董事长、总经理 | 202,065,500 | 40.21% | 202,065,500 | 37.95% | | 徐燕平 | 董事、副总经理 | 15,050,718 | 3.00% | 15,050,718 | 2.83% | | 罗红志 | 董事 | | | | | | 李纳 | 董事 | | | | | | 何谦 | 独立董事 | | | | | | 仲维宇 | 独立董事 | | | | | | 李剑 | 独立董事 | | | | | | 俞汉昌 | 监事会主席 | 135,000 | 0.03% | 135,000 | 0.03% | | 董榜喜 | 监事 | | | | | | 赵阿荣 | 职工监事 | 28,500 | 0.01% | 28,500 | 0.01% | | 周国铨 | 财务总监 | 504,500 | 0.10% | 504,500 | 0.09% ...

保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 中信证券股份有限公司 关于 深圳市昌红科技股份有限公司 2022年度向特定对象发行A股股票 之 上市保荐书 二〇二三年九月 深圳市昌红科技股份有限公司 上市保荐书 声 明 中信证券股份有限公司接受深圳市昌红科技股份有限公司的委托，担任深圳市昌红 科技股份有限公司 2022 年度向特定对象发行 A 股股票的保荐机构，为本次发行出具上 市保荐书。 保荐机构及指定的保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司证券发行注册管理办法》 （以下简称"《注册管理办法》"）等有关法律、法规和中国证券监督管理委员会（以下 简称"中国证监会"）、深圳证券交易所（以下简称"深交所"）的有关规定，诚实守信， 勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具上市保荐书， 并保证所出具文件的真实性、准确性和完整性。 | 声 明 | | 1 | | --- | --- | --- | | 目 录 | | 2 | | 释 义 | | 3 | | 第一节 | 本次证 ...

经中国证券监督管理委员会《关于同意深圳市昌红科技股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2023〕1379 号）同意注册，公司向特定 对象发行 A 股股票 30,000,000 股，每股面值为人民币 1.00 元，发行价格为人民 币 13.79 元/股，募集资金总额为人民币 413,700,000.00 元，扣除不含税的发行费 用人民币 10,081,011.51 元，实际募集资金净额为人民币 403,618,988.49 元。 中信证券股份有限公司（以下简称"中信证券"）作为本次发行的保荐机构 （主承销商），已于 2023 年 8 月 28 日将募集资金扣除承销保荐费（含持续督导 费）划付至公司指定账户，立信会计师事务所（特殊普通合伙）已于 2023 年 8 月 29 日对上述资金到位情况进行了审验，并出具了《深圳市昌红科技股份有限 公司验资报告》（信会师报字[2023]第 ZL10414 号）。 二、《募集资金三方监管协议》的签订情况及募集资金专户情况 为规范公司募集资金管理和使用，保护投资者权益，根据《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所 ...

| 证券代码: | 300151 | 证券简称：昌红科技 | 公告编号：2023-066 | | --- | --- | --- | --- | | 债券代码: | 123109 | 债券简称:昌红转债 | | 深圳市昌红科技股份有限公司 关于变更保荐机构后重新签署募集资金 三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2023 年 8 月 22 日披露 了《关于更换保荐机构及保荐代表人的公告》（公告编号：2023-057），因公司聘 请中信证券股份有限公司（以下简称"中信证券"）担任 2022 年度向特定对象发 行 A 股股票的保荐机构，原保荐机构中天国富证券有限公司（以下简称"中天国 富"）尚未完成的前次公开发行可转换公司债券募集资金持续督导工作由中信证 券承接。 鉴于公司募集资金持续督导机构发生变更，为保证募集资金督导工作的正常 进行，保护投资者权益，根据《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市 ...

Group 1: Market Environment and Challenges - The company faces instability in the market due to multiple factors, including post-pandemic effects, a weak medical testing industry, and reduced market demand, leading to challenges in domestic orders [2] - International trade conflicts have also impacted the company's PCB business, with overall domestic market demand experiencing a decline [2] - Despite challenges, overseas factory orders remain stable, prompting the company to invest and expand its overseas production bases [2] Group 2: Business Performance and Future Outlook - The medical business has seen significant development opportunities during the pandemic, gaining recognition from numerous international clients and entering their supply chains [2] - The company plans to collaborate comprehensively with domestic and international clients in areas such as immunology, chemiluminescence, and molecular diagnostics in the second half of the year [3] - The market for medical consumables is substantial, with a single international IVD giant's annual global procurement reaching 8 billion RMB, and the blood glucose monitoring market potentially reaching several billion USD [4] Group 3: Product Development and Revenue Generation - The company is currently validating its wafer carrier products, which include FOUP and FOSB, but has not yet generated revenue from these products [4] - The company is focusing on differentiated product development strategies, starting with the most challenging 12-inch wafer carriers [4] - The mold projects reported are newly added concepts from the last 12 months, and the company will continue to disclose operational updates to keep investors informed [4]

Market Presence - The company primarily operates in developed markets such as Europe, the United States, and Japan, with a high proportion of foreign sales revenue[1] - The company has subsidiaries in various regions, including Hong Kong, Vietnam, and the Philippines, indicating a broad market presence[93] Financial Performance - The company reported a total revenue of 288,944,716.02 yuan for the reporting period, with a decrease of 604,874.57 yuan compared to the previous period[63] - The company's operating revenue for the first half of 2023 was ¥513,942,535.16, a decrease of 9.61% compared to ¥568,609,447.44 in the same period last year[114] - Net profit attributable to shareholders was ¥42,572,447.72, down 39.38% from ¥70,232,128.72 year-on-year, while the net profit after deducting non-recurring gains and losses was ¥33,847,103.77, a decrease of 43.82%[114] - The basic and diluted earnings per share were both ¥0.08, representing a decline of 42.86% compared to ¥0.14 in the previous year[114] - The company's total assets at the end of the reporting period were ¥2,089,105,420.94, down 6.52% from ¥2,234,719,706.75 at the end of the previous year[114] - The net assets attributable to shareholders decreased by 2.67% to ¥1,260,422,236.27 from ¥1,295,002,591.59 at the end of the previous year[114] - The company reported a net cash flow from operating activities of ¥94,875,766.23, an increase of 11.60% compared to ¥85,015,491.41 in the same period last year[114] Investment and Projects - The company has initiated a joint investment project with Hubei Dinglong Holdings to establish Zhejiang Dinglong Weibo Precision Technology Co., focusing on semiconductor wafer carrier manufacturing[25] - The semiconductor wafer carrier production facility is nearing completion, with production and testing equipment currently being debugged and samples sent to customers for validation[143] - The company has invested ¥5,681.22 million in the expansion of high-end medical equipment and consumables production lines, achieving an investment progress of 92.36%[183] - The high-end medical equipment and consumables production line expansion project has an investment commitment of RMB 32,500 million, with 92.36% of the investment completed[197] - The working capital supplement project has a total investment commitment of RMB 12,273.77 million, with 100% of the investment completed[197] Corporate Governance - The company has established a comprehensive corporate governance structure and internal control system to ensure fair treatment of all shareholders[14] - The annual shareholders' meeting held on May 16, 2023, had an investor participation ratio of 48.94%[76] - The board of directors and supervisory board have been re-elected during the annual shareholders' meeting[76] Environmental and Social Responsibility - The company is actively involved in environmental protection and sustainable development, adhering to relevant regulations for waste management[17] - The company emphasizes its commitment to environmental and social responsibilities in its report[95] - The company has no major environmental issues reported during the period[71] Research and Development - The company has established a relatively complete R&D system in precision mold design and manufacturing, focusing on protecting core technologies through patents and legal means[75] - The company has established a comprehensive R&D platform, including the Guangdong Precision Injection Molding Engineering Technology Research Center and the Shanghai Emerging Medical Devices and Life Sciences R&D Center[169] - The company focuses on precision mold design, manufacturing, and automation R&D, ensuring rapid response and diversified customization capabilities to meet customer needs[145] - The company has a strong R&D team with deep theoretical knowledge and rich industry experience, continuously advancing core technologies in high-precision medical molds and automation[146] - The company's R&D investment increased by 45.93% to ¥29,640,689.97, primarily due to higher salaries and stock-based compensation for R&D personnel[151] Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[6] - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves for the fiscal year 2023[87] - As of the reporting period, the company has a total of 502,507,912 shares outstanding, with no significant changes in shareholding structure[35] - The company has a total of 184,487,713 shares with limited sale conditions, representing 36.71% of total shares, which decreased by 2,878,731 shares[51] - The company holds 318,020,199 unrestricted shares, accounting for 63.29% of total shares, with an increase of 2,878,846 shares[51] Risk Management - The company has disclosed potential risks and corresponding countermeasures in the management discussion and analysis section of the report[100] - The company faces risks related to industry policy changes that could impact the medical consumables sector, emphasizing the need for adaptive management strategies[187] Cash Flow and Assets - Cash and cash equivalents at the end of the reporting period amounted to ¥372,380,581.71, representing 17.82% of total assets, a decrease of 5.14% from the previous year[176] - Accounts receivable totaled ¥254,658,369.27, accounting for 12.19% of total assets, down by 1.02% year-on-year[176] - Inventory stood at ¥159,464,287.85, which is 7.63% of total assets, reflecting a decrease of 0.83% compared to the previous year[176] - Fixed assets increased to ¥419,898,183.50, making up 20.10% of total assets, an increase of 4.69% from last year[176] - The company reported a total of ¥29,897,793.45 in intangible assets, down from ¥30,210,859.35 at the end of the previous year[178] Compliance and Legal Matters - The company has no significant related party transactions during the reporting period[39] - There are no derivative investments reported for the company during the reporting period[55] - The company has no violations regarding external guarantees during the reporting period[73] - The company has no significant litigation or arbitration matters during the reporting period[80] - The financial report for the first half of 2023 is confirmed to be true, accurate, and complete by the company's management[99] - The company has established a dedicated account for the management of raised funds, ensuring strict compliance with the regulatory agreement[197] - No changes in the use of raised funds have been reported, maintaining a 0.00% change ratio[197] - The company has disclosed that the use of raised funds is in good condition, with no significant violations reported[197]

2023 年上半年，公司不存在控股股东及其他关联方非经营性占用公司资金 的情况，也不存在以前年度并累计至报告期的关联方违规占用资金情况。 （二）公司对外担保情况 我们根据有关规定，通过对报告期内公司对外担保情况及关联方资金占用情 况的审核，发表如下独立意见： 2022 年 8 月 31 日，公司为全资子公司深圳市柏明胜医疗器械有限公司（以 下简称"深圳柏明胜"）向中国银行股份有限公司坪山支行申请 500 万元的流动 资金借款提供连带责任担保。 2023 年 2 月 28 日，公司为深圳柏明胜向中国银行股份有限公司坪山支行申 请 600 万元的流动资金借款提供连带责任担保。 截止 2023 年 6 月 30 日，公司及公司子公司累计对外担保余额为 1,100 万元， 占公司 2023 年半年度净资产的 0.87%。 深圳市昌红科技股份有限公司 独立董事关于第六届董事会第四次会议相关事项 的专项说明和独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规、规范性文件及《公司章 程》和《独立董事工作制度》的有关规定，作为深圳市昌红科技股份有限 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2023-061 | | --- | --- | --- | | 债券代码: 123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次会议召开情况 1、深圳市昌红科技股份有限公司（以下简称"公司"）第六届董事会第四次 会议（以下简称"本次会议"）于 2023 年 8 月 29 日上午在公司 1 号会议室以现 场结合通讯表决方式召开。 2、本次会议通知时间及方式：会议通知于 2023 年 8 月 22 日以电子邮件及 短信等方式送达给全体董事、监事和高级管理人员。 3、本次会议应出席董事 7 名，实际出席会议的董事 7 名。 4、本次会议主持人：公司董事长李焕昌先生 公司监事和高级管理人员列席本次会议。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露 的《2023 年半年度报告》及《2023 年半年度报告摘要》（公告编号：2023-063）， 《2 ...